The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies. The competitive landscape for biosimilar ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on comparative ...
FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability. The FDA has issued draft guidance that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback